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Risk-stratification and treatment intensification according to minimal residual disease (MRD) analysis has improved outcomes of patients with acute lymphoblastic leukemia (ALL). 1, 2 However, a significant proportion of patients with T-cell ALL (T-ALL) still experience early relapse or refractory disease. Robust prognostic markers able to identify high-risk patients at diagnosis have proved challenging, and riskadapted management for T-ALL remains an unmet need. The work presented here
shows that the molecular marker, absence of biallelic deletion at the TRG locus, does not have a poor prognostic impact on the outcome of pediatric and adolescent patients with T-ALL treated on the risk-directed protocol of the MRC UKALL2003 trial.
Early T-cell Precursor (ETP) T-ALL identified by immunophenotyping was
previously reported to confer a poor prognosis in pediatric, adolescent and adult patients. 3, 4 However, immunophenotyping was found to underestimate the number of patients with an ETP gene-expression signature, 5 and inter-laboratory diagnosis for this immunophenotype is not standardized. Moreover, gene-expression profiling is not widely utilized for clinical use. Therefore, an alternative molecular method based on the V-J recombination status of the T-cell receptor gamma (TRG) gene has been described. 6 Given that TRG recombination occurs early during T-cell development, 7 cells that have not undergone biallelic deletion at the TRG locus have been termed 'ABD' (Absence of Biallelic Deletion), with the majority of such ABD T-ALL cases having an ETP-ALL gene-expression signature. 6 Consistent with the original reports of ETP-ALL, 3 ABD was reported to be associated with inferior survival, 6 although the patients studied were not treated on MRD risk-directed protocols. Thus we investigated whether ABD status adds further prognostic information for pediatric and 3 adolescent patients with T-ALL treated on the MRC UKALL2003 trial that used MRD risk to direct treatment intensity. 1, 8 Whole genome amplified (WGA) DNA was available from diagnostic samples of 152 of 393 (39%) T-ALL patients treated on this trial. 9 Full details of the patient cohort, trial protocols, methods and statistical analyses are described in the Supplementary Baseline characteristics and survival outcomes of these 152 patients were not significantly different from the 241 patients not included in the study (Tables S1-2, Figure S1 ).
The TRG quantitative polymerase chain reaction (qPCR) assay determined fold change using the comparative
∆ ∆
CT method with ANLN as the reference gene (TRG:ANLN), as previously described. 6 There was good agreement between results from WGA material and their corresponding non-WGA sample where available confirmed using COA1 as an alternative reference gene ( Figure S2C ). TRG locus deletions were also determined using data from Illumina CytoSNP-850K arrays.
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By qPCR, 23 of 152 samples (15%) were classified as ABD, 110 (72%) as non-ABD, and 19 (13%) were indeterminate (16 with fold change 0.26-0.49; 3 with fold change >0.5 but blast count <50%) ( Figure 1A ). Baseline characteristics and survival of the 19 patients with indeterminate status were similar to the other 133 patients (Tables   S3-4 , Figure S3 ). Baseline characteristics of the 133 patients according to ABD status are outlined in Table 1 . Of these, 118 also had SNP array results at the TRG locus that were concordant with the qPCR findings (Figure 1 B-C), including 22 ABD patients;
array data was uninterpretable or not available for the remaining 15 cases.
However, there was no statistically significant difference in overall survival (OS)
between the ABD and non-ABD groups (5-year OS, 87% vs 90% respectively; hazard ratio (HR) 1.67, 95% confidence intervals 0.54-5.17; P=0.37) ( Figure 2A ; Table S5 ).
There was also no significant difference in the relapse-free survival (RFS) (82% vs 89%; HR 1.58, 0.52-4.86; P=0.42) ( Figure 2B ; Table S5 ). Although there was a trend towards an inferior event-free survival (EFS) in the ABD group, this did not reach statistical significance (78% vs 85%; HR 2.12, 0.88-5.12; P=0.09) ( Figure 2C ; Table   S5 ), and was impacted by 7 non-relapse events in the ABD group (1 infection-related death at induction, 4 deaths from causes other than ALL and 2 second malignancies).
We have previously reported that patients treated on this trial with T-ALL and NOTCH1/FBXW7 double-mutant status had excellent OS (100% additional prognostic significance of ABD in this subgroup, which would need to be addressed in a larger prospective trial.
Our data is in marked contrast to the results from another study where the ABD subgroup, identified using the same TRG qPCR assay, was associated with a dismal outcome (5-year OS: 25% vs 72% in the ABD and non-ABD groups respectively). 6 However, these patients were not treated using MRD-directed therapy, suggesting that differences in treatment protocols may impact on prognosis of this subgroup. Within the ABD group of our cohort, 11 patients (48%) received the more intensive chemotherapy arm, Regimen C, including all the 8 MRD-positive patients, although none of the ABD patients proceeded to an allogeneic stem cell transplant in first remission. Notably, there was no statistical difference in the RFS of ABD and non-ABD patients treated on Regimen C (P=0.21) ( Figure S6A , Table S6 ). The RFS for ABD patients treated on Regimens A or B was 100%, although it should be noted that none of them were MRD-positive ( Figure S6B , Table S6 ). There was a trend towards an increased risk of relapse in MRD-positive ABD patients when compared to MRDpositive non-ABD patients (HR 3.22, 0.83-12.52; P=0.07) ( Figure S6C ), which might relate to higher median MRD levels.
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The comparable survival of the ABD and non-ABD groups treated on the UKALL2003 trial is consistent with the outcome reported for patients on this trial according to their ETP status by immunophenotyping 12 . Moreover, the comparable survival between these two groups is also consistent with the outcome reported for ETP and non-ETP patients from other pediatric MRD risk-directed studies. 13, 14 In addition to this, our findings are similar to those recently reported for ABD status in 7 adult T-ALL patients treated using response-based risk stratification and therapy intensification, including allogeneic stem cell transplantation.
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In conclusion, our data indicate that in pediatric/adolescent T-ALL, ABD status does not add further prognostic information nor justify treatment escalation beyond what can already be inferred by MRD analysis using a risk-adapted protocol. 
Materials and Methods

Samples
Whole-Genome-Amplified (WGA) diagnostic genomic DNA (gDNA) from patient samples was as previously prepared. 3 
qPCR assay
The quantitative polymerase chain reaction (qPCR) assay was as previously described, 4 
Validation of fold change using a different reference gene
The fold change results that were indeterminate by the qPCR assay above TRG and COA1 assays were performed in triplicate using the same PCR reaction reagents, calibrator and conditions as described above and the TRG:COA1 fold change calculated. Standard curves using dilutions of gDNA from HEK293T cells were set up using the COA1 primers and the efficiency was comparable to that of the TRG primers (E=1.96 and E=1.84 for COA1 and TRG respectively).
The TRG:COA1 fold change led to the same ABD status assignment as that of the 
SNP array analysis
WGA gDNA samples were previously analyzed using the Infinium CytoSNP-850K
Beadchip array (Illumina, Essex, UK). 3 Log-R intensities and B-allele frequencies for each of the 62 SNP markers across the region hg19 chr7:38288270-38385938 which includes the TRG locus were assessed independently by 4 individuals and the TRG locus deletion status was scored as no or heterozygous deletion (ABD), or homozygous deletion (non-ABD).
Statistical Analysis
Survival curves were plotted using Kaplan-Meier analysis for overall survival (time from the start of treatment until death), event-free survival (time to relapse, secondary tumor or death, whichever came first) and relapse-free survival (time to relapse in those who achieved remission). Patients who died in remission were censored. Those who did not have an event were censored at the date last seen.
Comparisons between groups were carried out using Cox regression and the log rank test. Differences between the median Day 29 MRD results in the ABD and non-ABD groups was compared using the Wilcoxon Mann-Whitney test. Statistical analysis was conducted using STATA version 14.2 (STATACORP, Texas), MRD scatter plot drawn using GraphPad Prism 6 (GraphPad Software, Inc, California). P values derived using Chi-squared tests. * Patients without bone marrow results at day 8 or 15 (assumed to have rapid early response for treatment escalation decision) and two patients with conflicting slow early response data and bone marrow results. # Excluding the unknown group: P = 0.92. § Excluding the indeterminate group: P = 0.89.
Supplementary Tables
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Includes samples where there were either no targets for MRD assessment or the targets were not sensitive enough, and samples where MRD was either not analysed or was unevaluable due to the sample being inadequate or having missing data. WBC, white blood cell count; NCI, National Cancer Institute, CNS, central nervous system; MRD, minimal residual disease. Includes samples where there were either no targets for MRD assessment or the targets were not sensitive enough, and samples where MRD was either not analysed or was unevaluable due to the sample being inadequate or having missing data. WBC, white blood cell count; NCI, National Cancer Institute, CNS, central nervous system; MRD, minimal residual disease. 
